Quantum BioPharma Ltd. (NASDAQ: QNTM) Enlists Thermo Fisher’s Clinical Research Business to Launch Phase 2 Lucid-MS Trial

• New agreement moves innovative Lucid-MS treatment from planning into execution.
• Proprietary platform is designed around a novel neuroprotective approach that targets demyelination rather than solely modulating the immune system.
• Thermo Fisher’s clinical research business is a leading global contract research organization, with impressive expertise in central nervous system and MS studies.

Most multiple sclerosis (“MS”) drugs work by quieting the immune system. A new partnership shines the spotlight on a different approach — protecting the nerve’s own insulation — and sets up that treatment for a rigorous clinical test. Quantum BioPharma (NASDAQ: QNTM), a biopharmaceutical company developing therapies for neurodegenerative and metabolic disorders, has signed a Study Start-Up Agreement with the clinical research business of Thermo Fisher Scientific. The contract covers implementation of the phase 2 trial of Lucid-MS, Quantum’s lead drug candidate for MS.

Read More>>

NOTE TO INVESTORS: The latest news and updates relating to QNTM are available in the company’s newsroom at https://ibn.fm/QNTM

About InvestorWire

InvestorWire (“IW”) is a specialized communications platform with a focus on advanced wire-grade press release syndication for private and public companies and the investment community. It is one of 75+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, IW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, IW brings its clients unparalleled recognition and brand awareness. IW is where breaking news, insightful content and actionable information converge.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorWire website applicable to all content provided by IW, wherever published or re-published: https://www.InvestorWire.com/Disclaimer

InvestorWire
Austin, Texas
www.InvestorWire.com
512.354.7000 Office
[email protected]

InvestorWire is powered by IBN

This contant was orignally distributed by InvestorBrandNetwork (IBN). Blockchain Registration, Verification & Enhancement provided by NewsRamp™. The source URL for this press release is Quantum BioPharma Ltd. (NASDAQ: QNTM) Enlists Thermo Fisher’s Clinical Research Business to Launch Phase 2 Lucid-MS Trial.